Compare Analog Devices, Inc. (ADI) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs BioNano Genomics Inc — how do they compare? Analog Devices, Inc. trades at $384 (market cap $187.67B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Analog Devices, Inc. is far larger — about 13738.7× BioNano Genomics Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ADI | BNGO | |
|---|---|---|
Market Cap | $187.67B | $13.66M |
Sector | Technology | Health |
52-Week High | $445.48 | $4.92 |
52-Week Low | $225.20 | $1.06 |
Enterprise Value | $192.92B | $16.26M |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.98, up 0.27% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $472.29 highlight positive momentum. The company maintains robust profitability with a 26.01% net income margin and a dividend payout of $1.10, supported by solid cash flow from operations of $4.81 billion in 2025.
Outlook remains favorable with projected revenue growth to $12.7 billion in 2026, though elevated valuation ratios and competitive pressures in semiconductors pose risks. Institutional buying and a lack of sell ratings underscore confidence, but investors should monitor debt levels and market volatility.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
